Post-ablative serum thyroglobulin is an independent predictor of recurrence in low-risk differentiated thyroid carcinoma: a 16-year follow-up study
- PMID: 20813788
- DOI: 10.1530/EJE-10-0553
Post-ablative serum thyroglobulin is an independent predictor of recurrence in low-risk differentiated thyroid carcinoma: a 16-year follow-up study
Abstract
Objective: To study whether post-surgical and/or post-ablative thyroglobulin (Tg) concentrations may serve as independent predictors of disease recurrence in patients treated for TNM stage I or II well-differentiated thyroid carcinoma (WDTC).
Design: An observational retrospective study with a median follow-up of 16 years (range 10-24).
Patients and measurements: Post-operative and post-ablative Tg concentrations, age, tumour size, local infiltration and nodal metastasis at primary surgery as well as disease recurrences and cancer-specific deaths were evaluated in 495 low-risk (TNM stages I and II) patients, the majority of whom had total thyroidectomy and radioactive iodine remnant ablation as initial treatment.
Results: Fifty-one patients (10.3%) experienced disease recurrence during follow-up. In multiple logistic regression analysis, post-ablative Tg concentrations (odds ratio (OR) 3.72, confidence interval (CI) 1.71-8.05, P=0.0009) and local infiltration on primary surgery (OR 2.66, CI 1.03-6.90, P=0.04) were the only independent predictors of recurrence.
Conclusions: Post-ablative Tg concentration is a strong predictor of disease recurrence in WDTC.
Similar articles
-
[Postoperative radioiodine ablation in patients with low risk differentiated thyroid carcinoma].Med Clin (Barc). 2015 Jan 6;144(1):35-41. doi: 10.1016/j.medcli.2014.01.009. Epub 2014 Mar 5. Med Clin (Barc). 2015. PMID: 24613061 Review. Spanish.
-
[Patients treated for differentiated thyroid cancer with negative 131I whole-body scans and elevated thyroglobulin levels: a possible course].Rev Esp Med Nucl. 2007 May-Jun;26(3):138-45. Rev Esp Med Nucl. 2007. PMID: 17524307 Spanish.
-
Serum thyroglobulin levels at the time of 131I remnant ablation just after thyroidectomy are useful for early prediction of clinical recurrence in low-risk patients with differentiated thyroid carcinoma.J Clin Endocrinol Metab. 2005 Mar;90(3):1440-5. doi: 10.1210/jc.2004-1771. Epub 2004 Dec 21. J Clin Endocrinol Metab. 2005. PMID: 15613412
-
[Therapy concept in differentiated thyroid gland carcinoma--results of 25 years with 257 patients].Praxis (Bern 1994). 2000 Nov 2;89(44):1779-97. Praxis (Bern 1994). 2000. PMID: 11109916 German.
-
[Prospective therapy study in differentiated thyroid carcinoma].Schweiz Med Wochenschr. 1995 Nov 18;125(46):2226-36. Schweiz Med Wochenschr. 1995. PMID: 8525342 Review. German.
Cited by
-
Higher adjuvant radioactive iodine therapy dosage helps intermediate-risk papillary thyroid carcinoma patients achieve better therapeutic effect.Front Endocrinol (Lausanne). 2024 Jan 17;14:1307325. doi: 10.3389/fendo.2023.1307325. eCollection 2023. Front Endocrinol (Lausanne). 2024. PMID: 38298190 Free PMC article.
-
Value of circulating neutrophil elastase for detecting recurrence of differentiated thyroid cancer.Endocr Connect. 2023 Nov 20;12(12):e230400. doi: 10.1530/EC-23-0400. Print 2023 Dec 1. Endocr Connect. 2023. PMID: 37909732 Free PMC article.
-
Establishing a Cutoff Serum Thyroglobulin Value for the Diagnosis and Management of Well-Differentiated Thyroid Cancer.World J Nucl Med. 2023 Sep 6;22(3):208-216. doi: 10.1055/s-0043-1771286. eCollection 2023 Sep. World J Nucl Med. 2023. PMID: 37854090 Free PMC article.
-
Comparison of Radioactive Iodine Activities in Terms of Short- and Long-term Results in Ablation Therapy in Patients with Low-risk Differentiated Thyroid Cancer.Mol Imaging Radionucl Ther. 2023 Jun 20;32(2):112-116. doi: 10.4274/mirt.galenos.2022.05826. Mol Imaging Radionucl Ther. 2023. PMID: 37337764 Free PMC article.
-
Radioiodine (131I) treatment decision-making for low- and intermediate-risk differentiated thyroid cancer.Arch Endocrinol Metab. 2023 Mar 10;67(2):197-205. doi: 10.20945/2359-3997000000538. Epub 2023 Jan 17. Arch Endocrinol Metab. 2023. PMID: 36651706 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical
Miscellaneous
